Market Access Today’s Post

 Agon at CPHI Middle East in Riyadh, Saudi Arabia! We were honored to participate in this transformative event, engaging with partners, industry leaders, and new connections to shape the future of healthcare and pharmaceuticals.  Watch Our Video! Experience the highlights of Agon’s journey at CPHI Middle East! From inspiring panel discussions to meaningful connections, witness the energy and innovation that drove this incredible event. Click below to watch!  Panel Discussions We Were Honored to Join:  Pharmaceutical Localization and Sustainable Access to High-quality Healthcare  This panel focused on strategies to enhance local pharmaceutical manufacturing and ensure sustainable access to quality healthcare products.  Speakers: Yara Almouti Amgad Talaat Fahad AlButhi Ashraf Al Grain  Regional Spotlight – Oman  A deep dive into Oman’s pharmaceutical potential, highlighting regional advancements and opportunities in healthcare.  Speakers: Yara Almouti Hamid Saif Al-Sabahi Sofie Tolk Damith D.  Scaling Up Digital Innovation: Revolutionizing R&D to Patient Care within the Pharma Industry (CME Accredited)  Discussed cutting-edge digital innovations transforming the journey from R&D to patient care in the pharma industry.  Speakers: Yara Almouti Dr Nadia Cheaib Abdulaziz Alhomod MD, MS, FACEP, FAMIA @GloriaLam  Paving the Way for Young Pharmacists to Enter the Pharmaceutical Industry: Building Capacity and Incentive Programs (CME Accredited)  Explored initiatives to empower young pharmacists through capacity-building programs and industry incentives.  Speakers: Yara Almouti Vivien Santillan Dr Nadia Cheaib Venus Elrayes  We extend our deepest gratitude to everyone who made this event a success, Together, we are paving the way for a brighter future in healthcare! #AgonAtCPHI #CPHIMiddleEast #PharmaInnovation #PharmaLeaders #SustainableHealthcare #DigitalTransformation #R&DEvolution #YoungPharmacists #PharmaNetworking #RiyadhEvents #PharmaLocalization #FutureOfHealthcare #AgonPharma #PharmaLeadership #GlobalHealthcare #HealthcareInnovation #LifeSciences #PharmaTrends #PharmaEvent #HealthcareLeaders #PharmaGrowth #CPHISaudiArabia #PharmaceuticalDevelopment #PharmaOpportunities #GlobalNetworking #AgonWorldwide #BetterHealthcare #EmpoweringPharmacists #InnovativePharma #MiddleEastPharma #PharmaIndustryEvents

Thank you to the esteemed industry leaders and experts – Alaa Darwish, Dr Srikanth Rajagopal, Mohamed Amir, Firat Incioglu, Rina Chotai, and Hasan Kapar – for joining us at the Waldorf Astoria DIFC in Dubai for a thought-provoking roundtable discussion on "Unlocking the Market: Strategies for Pharmaceutical Pricing, Access, and Tenders in the GCC" earlier this month. The event provided a valuable platform to examine the critical role of national tenders in improving access to safe and effective medicines across the region. Experts engaged in an insightful dialogue on the current state of tender practices, delving into the evolution of these systems and their impact on the pharmaceutical industry, particularly in relation to various drug types. The conversation also focused on identifying key principles and best practices for designing a national tender system that ensures fair pricing, accessibility, and operational efficiency. Stay tuned for a report highlighting the key discussion topics and emerging trends. Discover more about Clarivate’s market-leading intelligence and transformative data technology here: https://lnkd.in/gD-vvkum #Pharmaceuticals #MarketAccess #Healthcare #Tenders #PharmaStrategy #HealthcareInnovation #Dubai

🔒 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀🔒 As pharmaceutical companies look to expand their global footprint, Saudi Arabia is becoming an increasingly attractive option, serving as a gateway to the Middle Eastern and North African markets. At Inbeeo, we appreciate that aligning with the Saudi Arabia’s vision2030 and navigating reimbursement pathways will be critical to successful launches in this market. 🌟 𝗩𝗶𝘀𝗶𝗼𝗻 𝟮𝟬𝟯𝟬 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁: Saudi Arabia’s Vision 2030 plan allocates significant resources to healthcare, focusing on enhancing service access, improving quality, and strengthening preventive measures. This initiative presents an opportunity for pharmaceutical companies to align their strategies with national goals regarding improving healthcare. 🏥 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀: •   𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗦𝗲𝗰𝘁𝗼𝗿: Price and registration are often sufficient for access, with individual hospitals requesting additional data. •   𝗣𝗮𝗿𝗮𝗹𝗹𝗲𝗹 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘀𝗮𝘁𝗶𝗼𝗻: Early reimbursement and physician engagement can raise product profiles and increase uptake through patient access programmes. •   𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 (𝗠𝗼𝗛) 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: National access is granted through the engagement of the MoH stakeholders, with regional Pharmacy and Therapeutic Committees (P&TCs) evaluating clinical and economic data, leading to the inclusion of the product on the Saudi National Formulary. 📊 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀: •   𝗟𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟱: These guidelines will mandate the submission of cost and budget impact analyses, with decisions from other influential HTA bodies playing a significant role. •   𝗖𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗲𝘀𝗵𝗼𝗹𝗱𝘀: SAR 50k-75k (equating to ~£10k-15,500) will be implemented from 2025. Saudi Arabia's strategic initiatives and evolving reimbursement pathways offer a viable opportunity for broadening access to innovative treatment options. By fully understanding the objectives and mechanisms linked to vision2030, companies can navigate the complexities of the market and achieve sustainable success. Written by Katie Hill, our Senior Associate Here at Inbeeo, we can support companies with aligning and developing their launch strategies for Saudi Arabia, with further adaptation to the MENA region. Contact us today! #Pharmaceuticals #Healthcare #SaudiArabia #Vision2030 #MarketEntry #HealthcareInnovation #PharmaGrowth

Advancing Healthcare Innovation and Regulatory Excellence at the 2024 SAAPI Conference At the 2024 SAAPI Conference, held at the CSIR International Convention Centre, SAHPRA CEO Dr. Boitumelo Semete-Makokotlela delivered a compelling keynote address focused on SAHPRA’s mission to provide safe, efficacious, and quality medicines and health products. Emphasizing the importance of patient safety and access, Dr. Semete-Makokotlela highlighted SAHPRA's commitment to being agile and responsive while maintaining high standards of safety, quality, and efficacy. She also stressed the importance of collaboration, indicating that SAHPRA is open to engagement with various stakeholders to improve access to essential health products for South Africans. The conference theme, "Engage and Empower: Pushing the Frontiers of the Pharma Industry," was further explored through presentations by various SAHPRA officials. Discussions covered the reliance approach to medicines registration, safety signal management, and the use of e-signatures to enhance document integrity. The event underscored SAHPRA's dedication to innovative regulatory practices and their efforts to streamline processes, ultimately aiming to foster a responsive and accessible healthcare system. This aligns perfectly with Vicore Health’s commitment to regulatory excellence and innovation. Vicore Health is dedicated to advancing healthcare by supporting regulatory frameworks that enhance drug safety, efficacy, and access, thereby contributing to a robust pharmaceutical industry capable of meeting the evolving healthcare needs of the population. This synergy highlights the potential for greater harmonization and collaboration in the pharmaceutical sector, driving forward shared goals of improving public health outcomes. Find out more here: https://lnkd.in/dBRpPWKf #PharmaInnovation #HealthcareReform #SAAPI2024 #SAHPRA #PatientSafety #RegulatoryExcellence #HealthcareAccess #PharmaIndustry #PublicHealth #Efficacy #QualityMedicines #PharmaceuticalRegulation Read the full article here: https://lnkd.in/eBSzzkZa

🌍 Spotlight on GÖG 🌍 We are proud to have the Austrian National Public Health Institute (Gesundheit Österreich GmbH) as a key partner in the PROCURE project. 🔎 Who is GÖG? GÖG is the institution responsible for researching and planning public healthcare in Austria and acts as the national competence and funding centre for the promotion of health. GÖG has extensive knowledge about pharmaceutical systems and policies in European countries and beyond, and has been designated as WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. The project team has vast expertise in conducting policy-relevant research on the procurement of medicines in European countries. GÖG has led a large-scale study on best practices in the public procurement of medicines, commissioned by European Health and Digital Executive Agency (HaDEA) on behalf of the European Commission. This study mapped public procurement practices for pharmaceuticals in 32 European countries using desktop research, interviews, and quantitative data (TED), resulting in detailed country fact sheets and an assessment of the possible impacts of procurement practices. GÖG has previously led the Pharmaceutical Health Information System (PHIS), which examined procurement practices in hospitals in 27 European countries. 🚀GÖG is responsible for coordinating national efforts and contributing to the overall success of the PROCURE project. This includes: ·        Establishing a “country node” and compiling an “ID Card” for Austria, describing the national healthcare and procurement systems and practices. ·        Supporting the development of the methodology for the study on healthcare systems and procurement practices in Europe. ·        Participating in the Delphi process to identify key elements for successful public procurement practices in the healthcare sector. Experts from GÖG, alongside additional experts from Austria, will bring in their views on potential improvements in current procurement mechanisms. ·        Participating in working groups to develop recommendations, ensuring they reflect the Austrian context. ·        Contributing to conferences, including the final conference, and disseminating information through GÖG’s own networks. As a public health institute focusing on research on pharmaceutical policies and systems, the staff at GÖG brings in a ‘policy view’ and analyses how procurement practices may interact with other characteristics of the healthcare system. GÖG aims to leverage insights from PROCURE to contribute to more effective and resilient healthcare procurement practices. Stay tuned to learn more about the other partners in the consortium and their roles in the PROCURE project, making healthcare procurement more resilient and efficient across the European Union! #EU4Health #EUfunded #HealthUnion #HealthcareInnovation #HealthUnion #procureproject #PublicProcurement #ActiveAgeing #EUProjects

National Primary Health Care Development Agency (NPHCDA) has collaborated with the National Institute for Pharmaceutical Research and Development (NIPRD) to improve the implementation of evidence-based innovations in the health sector of Nigeria.

Yesterday, we received the latest MAT report from IQVIA, and the numbers are impressive! The UAE pharmaceutical market is currently valued at $4.1 billion USD, with a growth rate of 16.5%. This dynamic growth showcases the UAE's commitment to advancing healthcare and pharmaceutical innovation. What Insights I could drive were: Alimentary Tract and Metabolism: Leading the market, reflecting the increasing focus on gastrointestinal health and diabetes management. Retail Pharmacy Boom: Contributing significantly to overall market growth, driven by rising consumer awareness and demand for OTC products. Surge in Innovative Treatments: Especially in chronic disease management, with companies investing heavily in research and development. Government Support: Playing a pivotal role in healthcare sector growth through policies promoting investment and establishment of world-class medical facilities. Digital Health Solutions: Telemedicine and e-pharmacies are becoming integral parts of the healthcare system, enhancing patient access to services and medications. At Morphosis, we are committed to leveraging these insights to drive effective pharmaceutical marketing strategies. By understanding market trends and consumer behavior, we create targeted campaigns that resonate with healthcare professionals and patients alike. Our goal is to help our clients navigate this dynamic landscape and achieve sustainable growth. #pharmaceuticalmarketing #healthcareinnovation #UAEpharma #marketinsights #voiceofmorphosis #pharmaceuticalmarketingagency

Yesterday's The Pharmaceutical Managers Institute Market Access Masterclass, proudly sponsored by Salutem Insights, was a fantastic opportunity to delve into the latest industry developments and gain actionable insights. With expert contributions from key industry leaders, the session covered a wide range of topics crucial to understanding the evolving landscape of market access in Ireland. Here are our key takeaways: 🔹 𝗡𝗖𝗣𝗘 𝗨𝗽𝗱𝗮𝘁𝗲: The NCPE has expanded its team with 11 new staff (7 HTA Assessors & 4 Statisticians) to handle the growing volume of submissions in 2023. However, a backlog remains due to the surge in submissions. 🔹 𝗡𝗲𝘄 𝗕𝘂𝗱𝗴𝗲𝘁 𝗜𝗺𝗽𝗮𝗰𝘁 𝗧𝗲𝗺𝗽𝗹𝗮𝘁𝗲: Exciting news from the NCPE – a new Budget Impact Template is set to roll out by October 2024, promising more efficient processes. 🔹 𝗘𝗮𝗿𝗹𝘆 𝗖𝗼𝘀𝘁 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀: Ronan Mahon from University of Galway shared insights on how early cost-effectiveness analysis can help manufacturers assess the value of new medicines during clinical trials, offering critical insights from a health system perspective. 🔹 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗩𝗼𝗶𝗰𝗲 𝗶𝗻 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: Aoife Kirwan from Multiple Sclerosis Ireland Ireland highlighted the importance of integrating the patient perspective in the reimbursement process, especially in telling the "unmet need" story. 🔹 𝗔𝗜 𝗶𝗻 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: EY Ireland gave us a glimpse into the evolving role of AI in market access. While still in its early stages in Market Access, AI is already starting to add value in other areas. 🔹 𝗣𝗮𝘆𝗲𝗿 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 & 𝗧𝗶𝗺𝗲𝗹𝗶𝗻𝗲𝘀: Our MD, Sandra Redmond, shared insights from the Salutem Insights dashboard on what payers are focused on, timelines, and overcoming challenges in the reimbursement process. 🔹𝗩𝗼𝗶𝗰𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆: Leah Russell from Pfizer gave us an overview of the challenges facing the industry including the forthcoming Framework Agreement and time to reimbursement timelines. A big thank you to Fiona Dunphy and the PMI team for organising such a valuable event. We look forward to continuing the discussion and sharing more updates. If you'd like to learn more about these key topics or how Salutem Insights can support your Market Access strategy, get in touch today! #MarketAccess #HealthcareInnovation #HTA #IrishPharma #Reimbursement #HealthcarePolicy #SalutemInsights

The French pharmaceutical industry plays a significant role in both the national and global economy demonstrating strong performance across various key areas: 👭 Workforce: The industry employs a skilled and diverse workforce with hundreds of thousands working in research, development, production, and sales. It is known for offering high-quality jobs, contributing to France's standing as a leader in health innovation. 💶 Revenue: France’s pharmaceutical sector generates substantial revenue, making it one of the largest in Europe. This revenue reflects strong demand for both domestic and export markets, particularly in therapeutic areas such as oncology, cardiovascular, and infectious diseases. 📈 Investment Levels: The sector attracts significant investments, driven by both private capital and public funding. These investments fuel innovation and expansion, supporting the development of cutting-edge therapies and technologies. 💻 R&D Spending: A hallmark of the French pharmaceutical industry is its robust commitment to research and development. R&D expenditure remains high, supporting the creation of new treatments, and maintaining France’s competitive edge in global healthcare markets. 💊 Consumption: Pharmaceutical consumption in France reflects high healthcare standards, with a strong emphasis on quality medicines. The country has an advanced healthcare system that fosters steady demand for pharmaceuticals across various segments, ensuring both accessibility and quality care for the population. These key statistics underscore the vibrancy and competitiveness of the French pharmaceutical industry, highlighting its critical contribution to global healthcare and economic development. #frenchpharma #pharmaindustry #frenchhealthcare #ResearchDev #francepharmarevenue

Unveiling the Pulse of Progress: The Pharmaceutical Landscape in Saudi Arabia Responsibility! Innovation! Care! Qualities that define the flourishing pharmaceutical sector in the Kingdom of Saudi Arabia. As we navigate through the waves of our current healthcare expectations, KSA stands prominently as a beacon of progressive medical advancements and patient care excellence. - *Rapid Growth*: Saudi Arabia's pharmaceutical industry is on a powerful upward trajectory. Fueled by Vision 2030, the sector is not only expanding in economic size but also in global influence. - *Innovation at Core*: Home to cutting-edge research and development, the KSA is pioneering treatments that will benefit not only the local populace but the global community. - *Enhanced Accessibility*: Pharmaceutical companies in Saudi are stepping up by increasing the availability of high-quality medicines across the region. Ensuring health inclusivity remains a paramount priority. Why should this matter to us? As global citizens and professionals, the impact of Saudi's pharmaceutical expansion resonates beyond local markets. Its contributions toward global health security and innovation spearhead a plethora of opportunities for international collaborations and partnerships. However, amidst this growth, it is imperative to address the nuances and challenges faced by the industry—regulatory complexities, market competition, and the integration of technology in pharmaceutical practices. As these companies embrace more sophisticated technologies like AI and machine learning, the potential for personalized medicine becomes increasingly tangible. This is where the confluence of tradition meets innovation. Let us acknowledge the strides Saudi Arabia is making in the healthcare sector, and consider how collaboration could accelerate not only regional but global advancements in healthcare. Whether it's through sharing knowledge, investment, or strategic partnerships, there's a wealth of potential waiting to be unlocked in the sands of Saudi. **#Pharmaceuticals #SaudiArabia #HealthCareInnovation #GlobalHealth #Vision2030 #StrategicPartnerships**